1 Two phase III studies—Avastin for Renal Cell Cancer (AVOREN) 7 and Cancer and Leukemia Group B (CALGB) 90206 8 indicated significant improvements in PFS for bevacizumab plus interferon-α ...
“Our work has opened the door to a possible new method of treating a particularly aggressive cancer,” said Brennah Murphy, Ph.D., first author of the paper. “Ovarian cancer is infamous for resisting ...